Los Angeles Capital Management
NGM

Los Angeles Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Los Angeles Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,919
Closed -$156K – 1301
2022
Q3 		$156K Buy
+11,919
New +$181K ﹤0.01% 1188

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Los Angeles Capital Management's NGM Position: Q4 2022 in Review

Los Angeles Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 11,919 shares — an estimated $156K sold.

Los Angeles Capital Management first reported a position in NGM in Q3 2022 and held it in 1 quarter. The position peaked at $156K in Q3 2022. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

  • Los Angeles Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 11,919 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $156K.
  • Los Angeles Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Los Angeles Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $156K in Q3 2022.
  • 125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Los Angeles Capital Management's 13F filing for Q4 2022, filed 6 Feb 2023.